Key result
In middle-aged and elderly Japanese patients, the pharmacokinetic variability of bisoprolol was small (interindividual variability of oral clearance 22.0%) and correlated with renal function and body weight, but not CYP2D6 or CYP2C19 genotypes.
Why the study?
What are the pharmacokinetic parameters and variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients?
Observational (n=40)
No
What are the pharmacokinetic parameters and variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients?
The pharmacokinetic variability of bisoprolol is small in Japanese patients when body weight and renal function are considered for predicting oral clearance.
May guide bisoprolol dosing in Japanese elderly; leaves open validation and outcome trials before wider use.
The nonlinear mixed effects model (NONMEM) was used to analyze the pharmacokinetics of routinely administered bisoprolol in middle-aged and elderly Japanese patients. The subjects consisted of 29 males and 11 females with a mean age of 63.5+/-10.1. Data on the plasma concentration of bisoprolol from 94 blood samples obtained at steady-state following repetitive oral administration were analyzed using the NONMEM program, where a one-compartment model with repetitive bolus dosing was parameterized in terms of oral clearance (CL/F) and apparent volume of distribution (V/F). Individual CL/F values were correlated with body weight (WT) and creatinine clearance (CLcr). The relation between CLcr and the CL/F of bisoprolol was not altered by the CYP2D6 and CYP2C19 genotypes, gender, or age. The mean CL/F value estimated with NONMEM was 0.0612.WT+1.15.CLcr (l/h), and the mean V/F value was 2.61.WT (l). The residual interindividual variability of CL/F and V/F were 22.0% and 12.6%, respectively. The pharmacokinetic variability of bisoprolol is small even in routinely treated Japanese patients, provided that both body weight and renal function are taken into account for the prediction of oral clearance of the drug.
No takes yet. Share an insight, caveat, or question.
Taguchi et al. (2005) conducted an observational in Cardiovascular diseases (hypertension, angina pectoris, arrhythmias, mild congestive heart failure) (n=40). Bisoprolol was evaluated on Oral clearance (CL/F) and apparent volume of distribution (V/F). In middle-aged and elderly Japanese patients, the pharmacokinetic variability of bisoprolol was small (interindividual variability of oral clearance 22.0%) and correlated with renal function and body weight, but not CYP2D6 or CYP2C19 genotypes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: